Health Care • Biotechnology: Pharmaceutical Preparations
$1.89 ▲ +0.25
(+15.24%)
MKT CAP: $48.0M • VOL: 66.4K
52W L $1 52W H $5
ROARABLE / RQD
D- • 43/100
PIOTROSKI
3 / 9
SER // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $130.0K | $56.0K | $3.2M |
| YoY Revenue Growth % | +132.1% | -98.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$24.0M | -$17.0M | -$3.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$19.2M | -$11.1M | $5.3M |
| EBITDA (Normalized) | -$24.0M | -$17.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.0M | -$17.1M | -$2.5M |
| Capital Expenditures (CapEx) | $59.0K | $22.0K | — |
| Free Cash Flow (FCF) | -$18.0M | -$17.2M | -$2.5M |
| FCF Margin % | -80.0% | -80.0% | -78.5% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.1M | $3.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$37.0K | $641.0K | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SER.